2025年5月5日晚，永安药业公告陈勇被立案调查并实施留置。资料显示，永安药业在牛磺酸行业深耕多 年，已成为全球最大的牛磺酸生产基地，市场份额50%左右，产品广泛出口至世界各地，雀巢、可口可 乐等世界级公司均为该公司客户。 2025年上半年，永安药业营收3.674亿元，同比下滑13.72%；净利润1250万元，同比下滑76.19%。永安 药业表示，受市场行情低迷影响，上半年公司主营产品牛磺酸产销量及销售价格比去年同期都有所下 降，导致业绩承压。 近日，永安药业管理层在接受机构调研时表示，公司主要产品牛磺酸采用自行独创工艺，拥有多项发明 及实用新型专利，与同类产品相比具有价格、质量、品牌等竞争优势。未来，公司将深化核心技术研 发，不断提升核心竞争力。 （文章来源：证券时报） 证券时报记者严翠 被留置约4个月后，永安药业（002365）实控人、董事长陈勇解除留置措施。 9月3日晚，永安药业披露，近日，公司收到陈勇家属通知，其收到鹤峰县监察委员会出具的《解除留置 通知书》，鹤峰县监察委员会已解除对陈勇的留置措施。目前，陈勇已能正常履行公司董事长职责，公 司生产经营情况正常。陈子笛将不再代为履行公司董事长的职责。 ...

Key Points - Tianpu Co., Ltd. announced a suspension of trading for stock verification due to multiple instances of abnormal trading fluctuations from August 22 to September 3, with a reminder for investors about market risks [1] - China Shipbuilding Industry Corporation announced a share exchange ratio of 1:0.1339 for the merger with China Shipbuilding, with the stock ceasing to be listed from September 5, 2025 [2] - Chengdu Huamei reported that its 40G high-precision RF ADC chip is still in the trial production stage and has not achieved mass sales, indicating market demand uncertainty [2] - Taihe Technology's sulfide solid electrolyte project is currently in the trial production phase and has not generated sales revenue [3] - Robotech signed a contract worth approximately €946.50 million for fully automated silicon photonic packaging equipment, expected to positively impact the company's future performance [4] - Wento Holdings reported that its cinema and gaming businesses are still in the recovery phase post-restructuring, with potential uncertainties in future operations [5] - Xibu Muye's fresh milk production increased by 4.8% month-on-month in August [6] - China Shipbuilding announced the implementation of a share exchange merger with China Heavy Industry [6] - Gansu Energy plans to invest CNY 40.89 billion in a wind-solar integrated project [6] - Xinhua Medical's endoscope cleaning workstation received a Class II medical device registration certificate [6]

证券日报网讯永安药业（002365）9月3日在互动平台回答投资者提问时表示，截至2025年8月29日，公 司股东人数为59，210户。 ...

Group 1 - Shengtun Mining plans to repurchase shares worth between 500 million and 600 million yuan, with a maximum repurchase price of 11.82 yuan per share, aimed at employee stock ownership plans or equity incentives [1] - Kangnbei received a drug registration certificate for Linggui Shugan Granules, which is derived from traditional Chinese medicine and is used for treating phlegm and dampness due to Yang deficiency [2] - Zhangjiang Hi-Tech intends to publicly transfer 100% equity and related debts of Shanghai Jixin Rui Construction Technology Co., Ltd. with a total price not less than 151 million yuan [3] Group 2 - Shankai Intelligent won a bid for a metering device procurement project worth 13.318 million yuan from Hohhot Water Supply Company [4] - Hason Co. plans to jointly establish a supply chain company with a registered capital of 10 million yuan, in which Hason will hold a 10% stake [5] - Pudong Construction's subsidiaries won multiple major projects with a total amount of 1.271 billion yuan [6] Group 3 - Jinling Pharmaceutical received approval for the Phase III clinical trial of Olaratogrel tablets, which are used for treating moderate to severe pain associated with endometriosis [8] - Menohua's subsidiary obtained a drug registration certificate for Mosapride Citrate Tablets, aimed at improving gastrointestinal symptoms [10] - Shapuaisi's major shareholder plans to reduce holdings by up to 2% of the company's shares due to personal financial needs [11] Group 4 - Changyuan Power reported an August electricity generation of 3.771 billion kWh, a year-on-year decrease of 6.03% [15][16] - Xibu Livestock's August fresh milk production increased by 4.8% month-on-month but decreased by 7.27% year-on-year [19] - Yong'an Pharmaceutical's actual controller and chairman had their detention lifted, allowing them to resume normal duties [20] Group 5 - Jinkai Intelligent's director resigned due to work adjustments [22] - Xinhua Medical received a Class II medical device registration for an endoscope cleaning workstation [23] - Haishi Science and Technology's innovative drug HSK47388 received approval for a new indication clinical trial [25] Group 6 - Baotai Co. plans to participate in a land use rights auction in Baoji City with a starting price of 57.34 million yuan [26] - Minfeng Special Paper received a government subsidy totaling 11.2 million yuan [27] - Jiuchang Bio obtained a medical device registration for a heparin-binding protein assay kit [29] Group 7 - Jingao Technology plans to repurchase shares worth between 200 million and 400 million yuan, with a maximum price of 17.36 yuan per share [31] - Youxunda won a bid for a metering equipment project from China Southern Power Grid worth approximately 161 million yuan [32] - Qianli Technology reported an August vehicle sales increase of 168.55% year-on-year [32] Group 8 - Guangzhou Port expects an August container throughput increase of 1.2% year-on-year [32] - Kexing Pharmaceutical's GB08 injection completed the first subject enrollment for Phase II clinical trials [33] - Wu Ming Pharmaceutical plans to transfer 98.9% of its subsidiary's shares to a newly established wholly-owned subsidiary [34] Group 9 - Shanghai Electric's acquisition of K-Electric Limited shares has not yet completed the transfer [35] - Fulai New Materials plans to raise no more than 710 million yuan through a private placement [36] - Huaren Health's drug registration application for a new type of potassium ion competitive acid blocker has been accepted [37]

以下是第一财经对一些重要公告的汇总，供投资者参考。 张江高科公告，公司全资子公司上海张江集成电路产业区开发有限公司拟通过公开挂牌方式，式转让上 海集芯睿建筑科技有限公司100%股权及相关债权，挂牌总价格不低于1.51亿元。 德创环保：拟延期不超5个交易日回复问询函 德创环保公告，公司8月27日收到上交所出具的《关于对浙江德创环保科技股份有限公司控股子公司购 买华鑫环保40%股权暨关联交易的问询函》。为确保回复内容的准确性、完整性，经申请，公司拟延期 不超过5个交易日回复该问询函。 【品大事】 成都华微：4通道12位40G高速高精度射频直采ADC芯片尚未规模化销售 成都华微发布股票交易异常波动公告，公司发布的4通道12位40G高速高精度射频直采ADC芯片相关产 品仅向部分客户进行送样并已有意向订单，尚未实现规模化销售，存在市场需求不确定性、客户验证失 败等风险。公司尚无法预测新产品对公司当前及未来经营业绩的影响。 哈森股份：拟设参股公司 从事机器人零部件相关业务 哈森股份公告，公司拟与关联方苏州辰瓴光学有限公司、中科中成机器人技术(成都)有限公司、非关联 方广东至高共赢投资企业(有限合伙)共同出资设立中科中成供 ...

北京商报讯（记者 丁宁）9月3日晚间，永安药业（002365）发布公告称，近日，公司收到公司实际控 制人、董事长陈勇家属的通知，其收到鹤峰县监察委员会出具的《解除留置通知书》，鹤峰县监察委员 会已解除对陈勇的留置措施。目前，陈勇已能正常履行公司董事长的职责，公司生产经营情况正常。陈 子笛将不再代为履行公司董事长的职责。 ...

格隆汇9月3日丨永安药业(002365.SZ)公布，近日，公司收到实际控制人、董事长陈勇先生家属的通 知，其收到鹤峰县监察委员会出具的《解除留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置 措施。目前，陈勇先生已能正常履行公司董事长的职责，公司生产经营情况正常。陈子笛先生将不再代 为履行公司董事长的职责。 ...

人民财讯9月3日电，永安药业（002365）9月3日晚间公告，公司5月6日披露，公司实控人、董事长陈勇 被鹤峰县监察委员会立案调查并实施留置。近日，公司收到陈勇家属的通知，鹤峰县监察委员会已解除 对陈勇的留置措施。目前，陈勇已能正常履行公司董事长的职责，公司生产经营情况正常。 ...

智通财经APP讯，永安药业(002365.SZ)公告，公司实际控制人、董事长陈勇先生此前被鹤峰县监察委员 会立案调查并实施留置。近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解除 留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。 ...

特此公告。 潜江永安药业股份有限公司 潜江永安药业股份有限公司（以下简称"公司"）于 2025 年 5 月 6 日披露 《关于公司实际控制人、董事长被留置的公告》（公告编号：2025-31），公司 实际控制人、董事长陈勇先生被鹤峰县监察委员会立案调查并实施留置。 近日，公司收到陈勇先生家属的通知，其收到鹤峰县监察委员会出具的《解 除留置通知书》，鹤峰县监察委员会已解除对陈勇先生的留置措施。目前，陈勇 先生已能正常履行公司董事长的职责，公司生产经营情况正常。陈子笛先生将不 再代为履行公司董事长的职责。 证券代码：002365 证券简称：永安药业 公告编号：2025-50 公司指定信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》 和巨潮资讯网，公司发布的信息均以在上述媒体刊登的公告为准。敬请广大投资 者注意投资风险。 关于公司实际控制人、董事长解除留置的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 潜江永安药业股份有限公司 董 事 会 二〇二五年九月三日 ...